Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

May 17, 2024

BUY
$34.58 - $46.03 $2.67 Million - $3.56 Million
77,293 New
77,293 $3.15 Million
Q2 2023

Aug 14, 2023

BUY
$34.58 - $46.03 $2.67 Million - $3.56 Million
77,293 New
77,293 $3.15 Million
Q2 2022

Aug 15, 2022

SELL
$38.49 - $76.21 $9.29 Million - $18.4 Million
-241,396 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$58.27 - $118.99 $7.05 Million - $14.4 Million
-121,000 Reduced 33.39%
241,396 $17.5 Million
Q1 2021

May 17, 2021

BUY
$46.59 - $83.68 $16.9 Million - $30.3 Million
362,396 New
362,396 $29.1 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $929M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Portfolio

Follow Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main, based on Form 13F filings with the SEC.

News

Stay updated on Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main with notifications on news.